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Cardiovascular diseases (CVDs), especially those involving a systemic inflammatory
process such as atherosclerosis, remain the leading cause of morbidity and mortality
in patients with chronic kidney disease (CKD). CKD is a systemic condition affecting
approximately 10% of the general population. The prevalence of CKD has increased
over the past decades because of the aging of the population worldwide. Indeed,
CVDs in patients with CKD constitute a premature form of CVD observed in the
general population. Multiple studies indicate that patients with renal disease undergo
accelerated aging, which precipitates the appearance of pathologies, including CVDs,
usually associated with advanced age. In this review, we discuss several aspects
that characterize CKD-associated CVDs, such as etiopathogenic elements that CKD
patients share with the general population, changes in the cellular balance of reactive
oxygen species (ROS), and the associated process of cellular senescence. Uremia-
associated aging is linked with numerous changes at the cellular and molecular level.
These changes are similar to those observed in the normal process of physiologic aging.
We also discuss new perspectives in the study of CKD-associated CVDs and epigenetic
alterations in intercellular signaling, mediated by microRNAs and/or extracellular
vesicles (EVs), which promote vascular damage and subsequent development of CVD.
Understanding the processes and factors involved in accelerated senescence and other
abnormal intercellular signaling will identify new therapeutic targets and lead to improved
methods of diagnosis and monitoring for patients with CKD-associated CVDs.
Keywords: chronic kidney disease, cardiovascular diseases, reactive oxygen species, extracellular vesicles,
microRNAs, cellular senescence, epigenetic alterations, atherosclerosis
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INTRODUCTION
Chronic kidney disease (CKD) is defined as a systemic
pathology that affects approximately 10% of the population;
however, data showed differences in the prevalence of CKD
between countries (Hill et al., 2016). The prevalence of CKD
has increased markedly over the past decades due to aging
of the population worldwide and increase in incidence of
diabetes mellitus, which has become the primary cause of
CKD. Nowadays, CKD is considered a public health problem
that causes high rates of mortality in the population due
to the association with cardiovascular diseases (CVDs) (Go
et al., 2004). Thus, CVDs are prevalent in patients with
CKD, and subsequent CKD is a significant risk factor for
CVDs. Furthermore, patients with CKD are at increased risk
for cardiovascular events or death than for progression to
end-stage renal disease (ESRD) (Keith et al., 2004). Multiple
studies support the notion that patients with renal disease
suffer accelerated aging, which precipitates the appearance of
pathologies, including CVDs, usually associated with advanced
age (Stenvinkel and Larsson, 2013).
Considerable efforts have been made to slow the progression
of the disease and improve the quality of life in patients with
CKD. New pharmacological strategies do slow the progression of
CVDs, and reduce the morbidity and mortality of CKD patients
(Merino et al., 2010). Likewise, methods of renal replacement
therapy currently offer increased purification capacity and
reduced adverse effects. However, the development of CVDs in
patients with CKD has not yet been halted. This may be because
when CKD is diagnosed, vascular pathology is already advanced
and irreversible (Vanholder et al., 2005).
The causes of vascular damage in CKD are exceptionally
complex. Among the theories proposed in recent years to
explain the high frequency of CVDs in renal patients, one
states that senescence of peripheral blood cells (known as
immunosenescence) and vascular cells (known as vascular
senescence) may be involved in the initiation and perpetuation
of vascular pathology that appears early in patients with CKD
(Merino et al., 2010, 2011; Carracedo et al., 2013).
Some therapies used successfully in other pathologies, such
as CVDs have tested in trials to avoid the progression to
ESRD. Statins with a clearly cardioprotective role present non-
beneficial results in these CKD patients (Jun et al., 2011).
However, recent studies demonstrated that statins in high
doses might be improved the renal function (Sanguankeo
et al., 2015). In this regard, antiplatelet agents may also
be different effects in ESRD (Jun et al., 2011). Moreover,
other therapies among them, antioxidants, angiotensin receptor
blockers (ARBs) therapies, and angiotensin-converting enzyme
(ACE) inhibitors, improve the kidney function in ESRD
(Jun et al., 2011).
In this article, we review the cellular and molecular
mechanisms, as well as processes involved, in increased risk
for CKD-associated CVDs. Summarizing the current state of
knowledge on CKD-associated CVDs will aid in early diagnosis
and design of novel therapies that will improve the health and
quality of life in renal patients.
INCREASED RISK FOR CVDs IN RENAL
PATIENTS, THE CURRENT STATE OF
THE PROBLEM
Cardiovascular diseases are the main cause of morbidity and
mortality in CKD patients (Go et al., 2004). This may be because
CKD itself is an independent risk factor for CVDs, and is
associated with an increased prevalence of traditional and non-
traditional risk factors for CVDs. Both estimated glomerular
filtration rate (eGFR) and albuminuria are independently
associated with cardiovascular outcomes (Matsushita et al., 2015).
Even microalbuminuria without a decline in renal function is
associated with a twofold to fourfold increase in the risk for CVD
(Schiffrin et al., 2007). Furthermore, CVD alone, and numerous
risk factors for CVD, exacerbate the progression of this condition
and may be risk factors for CKD.
In patients with CKD, remodeling of the myocardium and
blood vessels leads to several cardiovascular complications
such as cardiomyopathy, atherosclerosis, arterial stiffness,
calcification, and subsequent ischemic heart disease, heart failure,
cerebrovascular and cardiovascular death, and progression of
renal disease including ESRD (Chen et al., 2018). However, CKD
patients present a high incidence of cardiovascular morbidity and
mortality that is not fully accounted for by traditional risk factors
and those mutual to CVDs and CKD such as age, hypertension,
diabetes mellitus, obesity, hyperuricemia, dyslipidemia, tobacco
use, family history, and male gender. Specific risk factors
for renal impairment include albuminuria, anemia, mineral
and bone disorders, malnutrition, toxic metabolites, endothelial
dysfunction, inflammation, and oxidative stress (Figure 1).
Patients with CKD have numerous risk factors for the
progression of cardiac dysfunction. Several non-traditional risk
factors, such as volume overload, anemia, albuminuria, abnormal
calcium-phosphate metabolism, inflammation, oxidative stress,
and endothelial dysfunction, play critical roles in this process.
Left ventricular hypertrophy (LVH) is closely related to the
occurrence of heart failure (HF) and is known to be an
independent risk factor for mortality (London et al., 2001).
Among traditional risk factors, hypertension can be both a
cause and a consequence of CKD, while dyslipidemia is another
important risk factor for both CVDs and CKD.
INFLAMMATORY ALTERATIONS IN CKD
AND THEIR RELATIONSHIP WITH THE
DEVELOPMENT OF CVDs
Inflammation, which is a new non-traditional risk factor and
consequence of reduced kidney function, is highly associated
with elevated cardiovascular risk in patients with kidney
disease (London et al., 2001). The inflammation transfers
to the blood and generates damage in distal tissues in the
progression of concomitant diseases such as CVDs (Cottone
et al., 2008). Epidemiological and clinical studies have shown a
close relationship between markers of inflammation and risk for
cardiovascular events (Cottone et al., 2008).
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FIGURE 1 | Risk factors for cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). Traditional risk factors (such as hypertension and
diabetes mellitus) and specific CKD risk factors (such as albuminuria or inflammation) lead to remodeling of the myocardium and blood vessels. This process may
contribute to the development and progression of cardiomyopathy, atherosclerosis, arterial stiffness, and calcification. Without treatment, these alterations may
progress to ischemic heart disease, heart failure, cerebrovascular disease, renal progression, and cardiovascular death.
In patients with CKD, traditional cardiovascular risk factors,
such as hyperlipidemia and hypertension, are associated with an
inflammatory process (Silverstein, 2009). Specific cardiovascular
risk factors in CKD patients, such as accumulation of uremic
toxins inherent to the use of renal replacement techniques,
promote inflammation and are also associated with CVDs
(Silverstein, 2009). The chronic, systemic, and low-grade
inflammation usually observed in patients with CKD is a
long and generalized process that shows no signs of acute
inflammation and is mediated by moderate levels of cytokines
and inflammatory mediators (Ramirez et al., 2006). The systemic
nature and low intensity of this inflammatory response indicate
lack of injury and no loss of functionality in these specific tissues;
injury and loss of function are distinctive features in both acute
and chronic inflammation (Furman et al., 2019). Conversely,
the damage generated by systemic inflammation (SI) causes a
deterioration in the general state, favoring tumor processes or
degenerative diseases such as CVDs (Ungvari et al., 2018).
A similar SI process that is associated with aging is
called inflammaging (Flynn et al., 2019). SI is considered
an adaptive response that causes systemic damage, leading
to the development of multiple pathologies, including CVDs
(Oishi and Manabe, 2016).
Chronic, low-grade inflammation can be determined by
measuring plasma levels of markers such as C reactive protein
(CRP) (Sproston and Ashworth, 2018) and cytokines such as IL-6
and TNF-α. In a longitudinal analysis, CRP, measured at baseline
during the Modification of Diet in Renal Disease (MDRD) study,
was an independent predictor of all-cause and CVD-caused
mortality (Levey et al., 1999). In dialysis patients, the association
of CRP with mortality was main at low CRP levels, the lower
CRP level, the lower mortality risk (Bazeley et al., 2011). Other
pro- and anti-inflammatory cytokines, including IL-10 and TNF-
α, may also play a role in the development of CKD-associated
CVDs (Ekdahl et al., 2017; Mihai et al., 2018).
Although the mechanisms triggering innate immunity and
associated inflammation in CKD are still scarce, in spite
of some studies have shown that low levels of bacterial
endotoxins reached the blood circulatory system in CKD
patients, stimulate CKD-associated pathways. Endotoxemia is
more prevalent in patients with CKD than in healthy population,
and it is linked with CKD-associated CVDs (Ramezani and
Raj, 2014; Sirich et al., 2014). Endotoxins, which act as pro-
inflammatory stimuli, is linked to endothelial dysfunction, one
of the earliest steps in the development of atherosclerosis.
Highlighted that there is no data that described the mechanism
in which the endotoxins from bacteria get into the circulation
of CKD patients. In case the patient undergoes dialysis, the
procedure may result the cause of the infection. However,
endotoxemia is noted in stages of CKD that precede dialysis
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(Wu et al., 2011), suggesting that factors unrelated to dialysis
contribute to this process.
Disruption of the healthy intestinal barrier, among other
factors, may facilitate the passage of bacterial endotoxins into
circulation. Two protein-bound uremic toxins, indoxyl sulfate
(IS), and p-cresyl sulfate, not removed by conventional dialysis
induce inflammation and oxidative stress, causing vascular
endothelial cell injury (Ramezani and Raj, 2014) and contributing
to progression of renal impairment (Sirich et al., 2014) and
CV-related mortality (Wu et al., 2011).
Therefore, physicians need to identify patients at risk and
implement early prevention and treatment strategies in these
patients. In practice, managing cardiovascular risk in patients
with CKD mostly involves reducing modifiable risk factors
such as hypertension, dyslipidemia, and disturbance of mineral
and bone metabolism. Furthermore, dialysis adequacy and
renal transplantation, preferably pre-emptive transplantation, are
considered optimal therapies for the reduction of cardiovascular
risk in these patients.
CHANGES IN CELLULAR BALANCE OF
REACTIVE OXYGEN SPECIES CAN
CAUSE CVDs IN CKD PATIENTS
Oxidative stress appears because of an imbalance between the
production and elimination of reactive oxygen species (ROS).
Moreover, oxidative stress is considered a hallmark feature of
CKD-associated CVDs and contributes to all-cause mortality
in this patient population. Also, physiological stress on the
body of CKD patients is increased in very early stages of
the disease, progresses parallel to the deterioration of renal
function and is further exacerbated in patients undergoing
dialysis (Liakopoulos et al., 2017, 2019b). In fact, ESRD patients
on both hemodialysis (HD) and peritoneal dialysis (PD) manifest
significantly enhanced oxidative stress compared with that of
predialysis uremic patients (Liakopoulos et al., 2017, 2019a,b).
However, the link between the initiation of CKD and oxidative
stress remains debated.
Aging per se is a physiological process. However, aging
is associated with several age-related diseases such as CVDs
and CKD. According to the “oxidative stress theory of aging,”
aging and age-related diseases are precipitated by chronic
oxidative stress (Sies, 1986). Therefore, because incidence of
CKD is high in older persons and age is considered the
most consistent risk factor for CVDs (O’Hare et al., 2007;
Elewa et al., 2012), CKD is often examined in the context
of aging (Nitta et al., 2013). Furthermore, other fundamental
mechanisms that characterize biological aging (López-Otín et al.,
2013), such as cellular senescence, mitochondrial dysfunction,
loss of proteostasis, or altered intercellular communication
(López-Otín et al., 2013), may also play central roles in the
pathogenesis of CKD-associated CVDs (Shimizu and Minamino,
2019). In this context, several studies have shown that CKD
promotes cellular senescence and accelerates premature aging
via diverse mechanisms in the internal milieu such as redox
state perturbations, oxidative damage, inflammation, toxicity,
and localized signaling mediated by growth factors (Stenvinkel
and Larsson, 2013; Dai et al., 2019).
Low-grade inflammation (involving increased levels of
circulating inflammatory mediators in the absence of infection),
which is another characteristic feature of aging and age-
related diseases (De la Fuente and Miquel, 2009), is a crucial
component of CKD (Mihai et al., 2018). Although the precise
mechanisms contributing to the high prevalence of inflammation
in CKD are not well established, ROS may potentially contribute
to inflammation during declining renal function (Cachofeiro
et al., 2008). Oxidative stress and inflammation are interlinked
processes (De la Fuente and Miquel, 2009). The highly reactive
ROS can alter cellular structures and functional pathways. This
triggers a vicious cycle in which inflammatory cells, stimulated
by cell damage caused by ROS, generate a state of oxidative
stress and amplified oxidative damage (Mihai et al., 2018).
Therefore, cross-talk between oxidative stress, inflammation, and
aging/senescence represents a fundamental triad contributing
to the development and progression of CKD-associated CVDs
(Cachofeiro et al., 2008; Popolo et al., 2013).
In CKD patients, a pro-oxidative physiologic state leads
to oxidative tissue damage (Cachofeiro et al., 2008; Puchades
Montesa et al., 2009; Popolo et al., 2013). Indeed, oxidative
stress and damage increase in later stages of CKD and
become severe in ESRD patients undergoing HD and PD
(Liakopoulos et al., 2017, 2019a,b). Several oxidative stress
parameters gradually increase when renal disease progresses
(Table 1), suggesting that a decline in renal function may
have a direct effect on the worsening of oxidative stress
(Dounousi et al., 2006; Khansari et al., 2009). HD and PD
procedures further exacerbate oxidative stress via different
underlying mechanisms. In HD patients, several factors, such
as duration of dialysis, biocompatibility of dialyzer membrane
and dialysate, intravenous iron administration, activation of
leukocytes, retention of uremic toxins, or anemia, contribute
to the development and accumulation of oxidative products. In
addition, the composition of PD dialysate solutions (such as
increased osmolarity, low pH, high-glucose content, and presence
of lactate buffer) can trigger oxidative stress in PD patients
(Liakopoulos et al., 2017, 2019a,b; Roumeliotis et al., 2019a).
However, PD is considered to be more biocompatible than HD.
Indeed, HD shows increased accumulation of pro−oxidants and
depletion of antioxidants compared with PD (Liakopoulos et al.,
2017, 2019a,b; Roumeliotis et al., 2019a).
Table 1 lists clinical studies on triggers of oxidative stress
and damage in patients with CKD and ESRD undergoing HD
or DP. The underlying mechanisms responsible for oxidative
stress in CKD include: increased production and decreased
clearance of ROS and other oxidant compounds, such as
reactive nitrogen species or chlorinated oxidants; impaired
function of antioxidant systems, including both enzymatic
[i.e., catalase, superoxide dismutase (SOD), glutathione
peroxidase (GPx)], and non-enzymatic [i.e., glutathione
(GSH), thioredoxins, and vitamins C, E, and A] systems
(Kobayashi et al., 2005; Popolo et al., 2013; Gondouin et al.,
2015); increased oxidation of lipids, proteins, and DNA.
Indeed, CKD patients show elevated levels of lipid-peroxidation
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TABLE 1 | Factors participating in oxidative stress and damage in patients with CKD, ESRD, and those undergoing HD or DP.
Number of patients Localization Parameters Results References
31 HC Whole blood GSH HC = mild > moderate > severe CRF = HD Ceballos-Picot et al., 1996
83 mild CRF Erythrocytes GSSG HC = mild < HD < moderate < severe CRF
HC < HD < mild = moderate = severe CRF
55 moderate CRF Plasma GPx HD < HC < mild < moderate < severe CRF
HD < HC = mild = moderate = severe CRF
47 severe CRF GSSG HD < PD < severe < moderate < mild CRF < HC
HD > PD > mild = moderate = severe CRF > HC
18 HD Cu/Zn-SOD
30 PD GSH
GSSG
31 HC Plasma AOPPs HC = mild < moderate < advance CRF Witko-Sarsat et al., 1998
73 mild CRF AGE-pentoside HC < mild < moderate < advance CRF
53 moderate CRF MDA HC < mild = moderate = advance CRF
36 advanced CRF GPx HC > mild > moderate > advance CRF
61 HC Serum TBARS; TAS HC = CRF Annuk et al., 2001
37 CRF RBCs LOOH HC < CRF
GSH HC > CRF
GSSG; GSSG/GSH HC < CRF
70 HC Plasma Thiols HC > CKD Oberg et al., 2004
60 CKD Carbonyls HC < CKD
F2-isoprotanes HC < CKD
CRP HC < CKD
IL-6 HC < CKD
67 HC Plasma MDA HC < CKD Puchades Montesa et al., 2009
32 CKD (stage 4) Carbonylated
protein
HC < CKD
F2-isoprotanes HC < CKD
GSH HC > CKD
GSSG/GSH HC < CKD
CAT; GR; GPx;
SOD
HC > CKD
8-OH-dG HC < CKD
21 HC PBMNs ROS HC < CKD Fortuño et al., 2005
22 CKD (stages 1 and 2) NADPH oxidase HC < CKD
38 HC Plasma Vitamin C HC > CKD > HD Gondouin et al., 2015
51 CKD (stages 3, 4 and 5) 50 HD RBCs Zn HC > CKD = HD
SOD HC = CKD > HD
XO HC < CKD < HD
MDA HC = CKD < HD
1539 HD Serum AOPPs HD > PD Zhou et al., 2012
556 PD MDA HD > PD
8-OHdG: 8-hydroxy deoxyguanosine; AGEs: advanced glycation end-products; AOPPs: advanced oxidation protein products; CAT: catalase; CKD: chronic kidney
disease; CRP: C-reactive protein; Cu: copper; GPx: glutathione peroxidase; GR: glutathione reductase; GSH: reduced glutathione; GSSG: oxidized glutathione;
GSSG/GSH: ratio of oxidized/reduced glutathione; HC: healthy controls; HD: hemodialysis; IL-6: interleukin 6; LOOH: lipid hydroperoxides; MDA: malondialdehyde;
PBMNs: peripheral blood mononuclear cells; PD: peritoneal dialysis; RBCs: red blood cells; ROS: reactive oxygen species; Se: selenium; SOD: superoxide dismutase;
TAS: total antioxidant status; TBARS: thiobarbituric acid reactive substances; XO: xanthine oxidase; Zn: zinc.
products [such as lipid hydroperoxides and malondialdehyde
(MDA), thiobarbituric acid-reactive substances (TBARS),
4-hydroxynonenal (HNE), and F2-isoprostanes], oxidized
LDL, protein carbonyls, advanced-oxidation protein products
(AOPPs), advanced-glycation end products (AGEs), as well
as 8-hydroxy-2′-deoxyguanosine (8-OH-dG) and 8-oxo-7,8-
dihydro-2′-deoxyguanosine (8-oxo-dG). These factors contribute
to atherosclerotic lesions in these patients (Popolo et al., 2013;
Sung et al., 2013; Daenen et al., 2019). Moreover, genetic
polymorphisms and mutations in DNA repair genes, such
as FAN1 or hOGG1, and DNA repair nucleases, are involved
in increased accumulation of damaged nuclear DNA, which
contributes to progressive loss of kidney function (Stenvinkel
and Larsson, 2013; Sung et al., 2013). Uremic toxins, such as
IS, homocysteine, and AGEs, contribute to early senescent of
endothelial cells, and also play critical roles in the development
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of CKD. In CKD patients, progressive deterioration of renal
function leads to the accumulation of uremic toxins, which can
promote oxidative stress and inflammatory pathways (Sung
et al., 2013). For instance, IS induces uncoupling of endothelial
nitric oxide synthase (eNOS) and increased expression and
activity of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidases, leading to increased levels of ROS and
endothelial dysfunction in patients with CKD (Yu et al., 2011;
Daenen et al., 2019). High IS concentration is a risk factor
for CKD-associated CVDs and accelerates the progression of
CKD (Yu et al., 2011; Sung et al., 2013). Moreover, IS enhances
the production of mitochondrial ROS and downregulates the
expression of cellular protective factors by activating NF-κB
and related signaling by nuclear factor erythroid-derived 2-like
2 (NRF2), hemeoxygenase-1 (HO-1), and NADPH quinone
oxidoreductase-1. In addition to causing increased levels of ROS,
this cascade also upregulates the production of pro-inflammatory
cytokines (Dou et al., 2007; Zakkar et al., 2009; Masai et al., 2010;
Hwang et al., 2019). Moreover, NRF-2 downregulates the
expression of proteins involved in mitogen-activated protein
kinase (MAPK) pathways, contributing to cellular apoptosis
and senescence (Zakkar et al., 2009; Tebay et al., 2015).
Figure 2 shows the relationship between oxidative stress and
CKD-associated CVDs.
In addition to formation and accumulation of pro-oxidant
molecules, CKD patients, especially those undergoing dialysis,
can also suffer a considerable downregulation in antioxidative
and defensive mechanisms. This is associated with several
factors, such as malnutrition, dietary restrictions, or loss of
vitamins and trace elements occurring during HD or PD
(Liakopoulos et al., 2017, 2019b; Roumeliotis et al., 2019a).
Implementing lifestyle interventions, such as administration of
exogenous antioxidants, in patients with CKD on dialysis may
downregulate the inflammation and oxidative stress associated
with CVD-linked morbidity and mortality even in early stages
of CKD (Liakopoulos et al., 2019a,b; Roumeliotis et al., 2019b).
Indeed, several studies have investigated the possible benefits
of exogenous antioxidant administration in both HD and
PD patients. Whether vitamins (B, C, D, and E), statins,
coenzyme Q-10, N-acetylcysteine (NAC), omega-3 fatty acids,
flavonoids, polyphenols, curcumin, green tea, and L-carnitine
are beneficial in HD and PD patients remains controversial.
Although these data are limited and mainly derived from
animal studies or small observational trials, they have generally
shown that daily intake of vitamin C and E, NAC, polyphenols,
curcumin, or flavonoids, combined with a standard urate-
lowering therapy, may act synergistically to ameliorate the
deleterious effects of hyperuricemia and oxidative stress in
FIGURE 2 | Relationship between oxidative stress and CKD-associated cardiovascular disease (CVDs). CKD leads to increased damage of biomolecules (such as
lipids, proteins, and DNA), impairment of the antioxidant system, increased levels of reactive oxygen species (ROS), decreased ROS clearance, and high
concentration of uremic toxins in circulation. This process increases the levels of oxidative stress. CKD is also associated with systemic inflammation, mitochondrial
dysfunction, loss of proteostasis, altered intercellular communication, and cellular senescence. Combined, these factors contribute to increased levels of oxidative
stress in this patient population. However, cellular senescence and inflammation also participate in the development and progression of CVDs.
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CKD (Liakopoulos et al., 2019a,b; Roumeliotis et al., 2019b).
However, further studies in large cohorts of HD and PD patients
are necessary to determine the causality between antioxidant
supplementation and clinical hard end-points of CVDs and all-
cause mortality.
IMMUNE ALTERATIONS IN PATIENTS
WITH CKD AND THEIR RELATIONSHIP
WITH VASCULAR PATHOLOGY
CKD is classically associated with immunodeficiency that
contributes considerably to all-cause morbidity and mortality
(Cohen and Hörl, 2012). Patients with CKD and those
undergoing renal replacement therapy show quantitative
alterations in components of the immune system and altered
functionality of these components. Numerous studies have
focused on relationships between immune-cell senescence and
early onset of CKD-associated CVDs.
The number and function of lymphoid cells suffer a
decrease associated with the loss of the renal function. This
is characterized by loss of thymic function, shortening of
telomeres, and expansion of memory T-cell populations, which
is compatible with the concept of premature immune aging
(Georgin-Lavialle et al., 2010).
Total lymphopenia is a marker of overall mortality in patients
on hemodialysis (Pahl et al., 2010; Saad et al., 2014). Patients
with ESRD or those undergoing renal replacement therapy show
a decreased response to specific pathogens and vaccines. These
patients also show an increased susceptibility to intracellular
pathogens and increased incidence of tumors compared with
the general population (Eleftheriadis et al., 2007). Different
subtypes of lymphocyte populations and immunoglobulins play
ambivalent roles in atherosclerosis. Some lymphocytes and
immunoglobulins (T-helper lymphocytes, natural killer cells,
T-cytotoxic lymphocytes, and B2 cells, and IgG- and IgE-
secreting cells) play a pro-atherogenic role, while others [Tregs,
B1a cells, innate response activator (IRA) B cells, Bregs, and
natural IgM-secreting cells] show protective functions in healthy
subjects (Tsiantoulas et al., 2015). A previous study has examined
the roles of different subtypes of T lymphocytes and their
cytokines in patients with CVDs and ESRD or those undergoing
renal replacement therapy (Danyan et al., 2013). In patients
with CKD, studies have focused on the roles of T lymphocytes,
increased numbers of Th17 cells, and their proatherogenic
activity (Danyan et al., 2013) (Figure 3).
The roles of B cells in the development of CKD-associated
CVDs are unclear. Patients undergoing hemodialysis frequently
develop lymphopenia B. This is due to increased cellular
apoptosis that results from decreased Bcl-2 expression, and
resistance to interleukin-7 (IL-7) and B-cell-activating factor of
the TNF family (BAFF), which is necessary for the differentiation
and survival of B lymphocytes (Fernández-Fresnedo et al., 2000;
Pahl et al., 2010). B cells are classified into subtypes B1 (B1a and
B1b) and B2 (Figure 3). Patients on hemodialysis have decreased
numbers of both B1 (atherogenic B1a) and B2 (proatherogenic)
lymphocytes, although the reduction in B1 lymphocytes is
FIGURE 3 | Changes in the immune system in CKD lead to the development
of CVD. The populations of classical (CD14++CD16-) monocytes in CKD
decrease, while those of intermediate (CD14++CD16+) and non-classical
(CD14+CD16+) monocytes increase. The intermediate (CD14++CD16+) and
non-classical (CD14+CD16+) monocytes promote inflammation and
proatherogenic milieu by upregulating the expression of adhesion molecules
and production of microvesicles (MVs) in the endothelium; this contributes to
the development of CVD in patients with CKD. Lymphopenia of both T and B
lymphocytes is observed in CKD. The T lymphopenia is caused by the
reduction of T regulatory cells (Treg), contrariwise the increase of
pro-inflammatory T helper 17 lymphocytes (Th17). These changes in
proportion of regulatory cells to proinflammatory cells can lead to
inflammation. B lymphopenia is caused by decreased numbers of B1 and B2
cells. The numbers of B1 lymphocytes generally show a greater decline than
those of B2, resulting in a B-lymphocyte imbalance. These two processes
also participate in the development of CKD-associated CVD.
generally more significant (Pahl et al., 2010). This milieu causes
a chronic imbalance favoring pro-endogenous B lymphocytes,
which increase the incidence of cardiovascular pathology.
A recent study, examining the roles of different lymphocyte
populations in the mortality of hemodialysis patients in
Spain, has shown that the number of B lymphocytes is an
independent risk factor for overall mortality in this patient
population. The study has shown that cardiovascular pathology
is the leading cause of mortality in these patients, and that
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a relationship exists between decreased B-cell numbers and
mortality from cardiovascular causes. The leading cause of
mortality in this study was cardiovascular, and in this aspect,
there was a relationship between the decrease in B cells and
the mortality of cardiovascular causes, confirming this data
with the determination of B lymphocytes at 12 months of
follow-up. Conversely, patients with a CD56+ lymphopenia
show a higher prevalence of mortality from infectious causes
(Molina et al., 2018).
Patients with ESRD currently show high mortality; therefore,
multiple parameters have been evaluated to predict the mortality
of this population (Floege et al., 2015). CD19 lymphopenia may
be a new marker for predicting the risk for morbidity and
mortality in patients on hemodialysis. Therefore, accurate and
timely diagnosis of CD19 lymphopenia in patients with ESRD
and those undergoing dialysis may lead to new therapeutic
targets against CKD.
The three subpopulations of peripheral blood monocytes,
identified in the innate immune system, are: classical
monocytes (CD14++/CD16-), existing mainly in healthy
subjects; intermediate monocytes (CD14++/CD16+); and non-
classical monocytes (CD14+/CD16+). Intermediate monocytes
(CD14++/CD16+) may be involved in the development of
atherosclerosis both in the general population and in patients
with CKD (Georgin-Lavialle et al., 2010; Merino et al., 2011).
CD14+/CD16+ monocytes are inflammatory cells with high
capacity to produce pro-inflammatory cytokines and possess
a robust dendritic-cell – like function. In peripheral blood
of elderly individuals and patients with CKD, non-classical
monocytes accumulate because of their increased resistance to
apoptosis (Ramírez et al., 2005). CD14+/CD16+ cells express
elevated levels of adhesion molecules and chemokines and
show high adhesion capacity on endothelial cells (ECs). In ECs,
CD14+/CD16+ cells induce increased expression of angiogenic
factors and production of microvesicles (MVs), which are
instrumental in induction of vascular damage (Merino et al.,
2011). Therefore, accumulation of CD14+/CD16+ monocytes
in peripheral blood plays a prominent role in inducing and
perpetuating the inflammatory process in elderly individuals and
patients with CKD and may have a direct relationship with the
development of CVDs (Figure 3).
CELLULAR ALTERATIONS IN THE
VASCULAR SYSTEM OF PATIENTS WITH
CKD
The sustained microinflammatory milieu that persists in patients
with CKD may be related to increased endothelial damage
(Merino et al., 2010; Cohen and Hörl, 2012). Changes in
endothelium are considered main factors indicating vascular
deterioration in the early detection of CVDs (Heine et al., 2012).
Endothelial aging, associated with age or induced by CKD, favors
endothelial dysfunction (Ramírez et al., 2005). In vitro studies
have shown that uremia determines a state of senescence in ECs,
which is also associated with chronic inflammation (Carracedo
et al., 2013). Therefore, both endothelial damage/dysfunction
and inflammation likely play important roles in the initiation
and progression of cardiovascular complications associated with
CKD (Ross, 1999).
Endothelial damage is associated with increased production
of extracellular vesicles (EVs). EVs serve as a signaling system
between the factors involved in the function and homeostasis of
the organism (Ekdahl et al., 2017). EVs are classified into three
types based on their biogenesis: exosomes, MVs, and apoptotic
bodies (Yáñez-Mó et al., 2015; van Niel et al., 2018). EVs are
produced by most cell types, especially when cells are in contact
with liquids. EVs are also produced under physiological and
pathological conditions, although their number and molecular
content differ under both conditions; indeed, of the potential
use of EVs as pathological markers is based on these differences
(Yuana et al., 2013). Aging and stress also induce changes
in EVs. EVs are involved in the origin and development of
various pathologies, and may be used as potential biomarkers
or therapeutic agents in patients with CVDs (Amosse et al.,
2017; Jansen et al., 2017; Dickhout and Koenen, 2018). EVs
are involved in the development of renal dysfunction (Karpman
et al., 2017; Lv et al., 2019), and can, therefore, be used in the
diagnosis of, and therapy against, these diseases (Zhang et al.,
2016). Elimination of EVs is currently used as a therapeutic
strategy (Tang and Liu, 2019). Endothelial MVs can serve as
useful biomarkers of CKD (Carmona et al., 2017a) because
endothelial damage is associated with CKD, and the release
of EVs is enhanced during endothelial injury. Uremic toxins
(such as IS) also induce a release of endothelial MVs (Carmona
et al., 2017b). Not only are plasma EVs modified in kidney
diseases, but the release of EVs from renal cells (epithelial
cells, podocytes, and tubular cells) is also altered. These kidney-
derived EVs can be isolated from urine and used as biomarkers
of CKD (Lv et al., 2019). Proteomic analyses have shown
differences in urinary EVs obtained from patients with kidney
diseases (Bruschi et al., 2019). These differences can be used to
establish stages in the development of kidney (Stokman et al.,
2019). In addition to serving as biomarkers, blood and urinary
MVs play functional and therapeutic roles in renal diseases
(Erdbrügger and Le, 2016; Kwon, 2019). For example, blood
EVs influence renal physiology via intranephron communication
(Lv et al., 2019), and their antibacterial (Hiemstra et al.,
2014) and protective effects (Bruno et al., 2009, 2016; Rovira
et al., 2017) have been demonstrated in kidney diseases. ROS
are important in the origination and development of CKD,
while MVs play antioxidative roles in this condition (Bodega
et al., 2019).; However, the specific roles of blood and urinary
MVs in redox dysregulation occurring in CKD have not
been determined.
MVs microRNAs MEDIATE
CKD-ASSOCIATED CVDs
MicroRNAs (miRNAs) are small, approximately 22-nucleotide
long strands of small non-coding RNAs that regulate post-
transcriptional processes (Ramshani et al., 2019; Rios et al., 2019).
Unlike RNA, miRNAs show high stability in fluids and can be
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reliably detected in the blood (Mitchell et al., 2008). MiRNAs
levels differ in healthy and diseased tissues (Liu et al., 2019)
and play a critical role in the maintenance of cardiovascular
homeostasis (Pfeifer et al., 2015). EV-associated miRNAs have
been studied extensively (Liu et al., 2019; Ramshani et al.,
2019). Numerous studies have shown that miRNAs can be used
as valuable pathological and therapeutic biomarkers in both
cells and EVs (Bekris and Leverenz, 2015; Lei et al., 2017).
Therefore, miRNAs may act as master regulators of signaling
pathways involved in CKD-associated CVDs. Moreover, different
profiles of EVs miRNAs in injured cells can be used as
diagnostic markers in various pathologies such as cancer
(Chen et al., 2019), viral infections (Yoshikawa et al., 2019), lung
diseases (Chen et al., 2017), ischemic stroke (van Kralingen et al.,
2019), CVDs (Bellin et al., 2019), and especially CKD-associated
CVDs (Jansen et al., 2017; Blaser and Aikawa, 2018). Cells from
vascular walls may selectively package miRNAs as molecular
cargo in EVs (Rios et al., 2019).
CKD-associated CVDs are associated with premature aging.
Accelerated aging of the vascular wall induces a senescent
phenotype in vessel cells, and particularly in ECs (Carracedo
et al., 2018a,b). EVs, released by senescent cells, are involved in
mechanisms driving the acquisition of this senescent phenotype
in ECs, which promotes the progression of CVDs. miRNA-loaded
TABLE 2 | Highlighted miRNAs mediate homeostasis of the vascular wall.
MiRNAs Expression Target Function Inverse (negative) regulated by References
Healthy ECs
miR-155 ↓(Down) Endothelial nitric oxide synthase
(eNOS)
Endothelium, vascular
relaxation
Inflammatory factor (TNF-α) (↑
miR-155)
Ballantyne et al., 2019; Chen
et al., 2019
miR-126 ↑(Up) Vascular endothelial growth factor A
(VEGF-A)
Angiogenesis Sprouty-related EVH1 domain 1
(SPRED-1) (↓ miR-126)
Alique et al., 2019; Ballantyne
et al., 2019
Physiological VSMC phenotype
miR-21 ↑(Up) Phosphatase and tensin homolog
(PTEN) B-cell lymphoma 2 (Bcl-2)
expression
SMC proliferation and
survival (anti-apoptotic)
Programmed cell death protein 4
(PDCD4)
Maegdefessel et al., 2015;
Ballantyne et al., 2019
miR-143/145 cluster ↑(Up) Transcription factors such as
Kruppel-like factor (KLF)-4,
(miR-145), KLF5, and ELK-1
VSMCs contractility
and proliferation
Angiotensin-converting enzyme
(ACE), KLF-4, myocardin
Maegdefessel et al., 2013;
Maegdefessel et al., 2015;
Metzinger-Le Meuth et al.,
2017; Ballantyne et al., 2019;
Vacante et al., 2019
TABLE 3 | MiRNAs involved in pathologies of the vasculature.
MiRNAs Expression Pathology Effect Via References
Damage ECs
miR-125b ↑(Up) Stimulation or ischemia Inhibition of in vitro tube formation ↓ VE-cadherin VEGF Vosgha et al., 2018;
Ballantyne et al., 2019
miR-126 ↓ (Down) Aging Senescence Hypoxia-inducible factor 1
(HIF-1)-α
Alique et al., 2019
CKD Endothelial dysfunction CXCL12 V-CAM 1 Metzinger-Le Meuth
et al., 2017
miR-34b-5p ↓ (Down) Cancer Proliferation and angiogenesis VEGF-A Maroof et al., 2017
miR-205 ↑(Up) Epithelial-to-mesenchymal
transition (EMT) and cancer
Inhibition of tumor growth VEGF-A Vosgha et al., 2018
VSMCs phenotype regulation
miR-21 ↓ (Down) Abdominal aortic aneurysms and
atherosclerosis (unstable plaques in
humans)
Antiproliferative RE1-silencing transcription
factor (REST)
Barwari et al., 2018
miR-143/145 cluster ↓ (Down) Vascular injury (vascular
remodeling), hypertension,
atherosclerosis, and
pulmonary-arterial hypertension
VSMC differentiation and
phenotypic switch
↓ Jag-1/Notch ↓
SRF/Myocardin
Vacante et al., 2019
Alteractions in ECs and VSMCs
miR-155 ↓ (Down) CKD osteoclastogenesis (vascular
calcification)
Differentiation of
monocytes/macrophages into
osteoclast-like cells
↓TNF-α Metzinger-Le Meuth
et al., 2017
miR-223 ↑(Up) CKD (vascular calcification,
osteoclastogenesis)
Transdifferentiation of VSMCs into
an “osteoblast-like” phenotype
RhoB/MEF2C/SMαA Metzinger-Le Meuth
et al., 2017
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EVs induce numerous injury-associated responses in other
vascular cells, leading to the development of CVDs (Carracedo
et al., 2018a). MiRNAs are essential to the homeostasis and
maintenance of EC activity (Ballantyne et al., 2019). Some of the
miRNAs involved in endothelial and vascular smooth muscle cell
(VSMCs) homeostasis are described in Table 2.
MiRNAs modulation is critical in numerous disorders. For
instance, miR-155 and miR-223 are responsible for the imbalance
between calcium and phosphate that is observed in the vessels
of patients with CKD. Moreover, patients with CKD show
a dysregulation of miR-155 and miR-223, which causes their
bones to lose calcium and phosphate; these ions are then
accumulated in the vascular wall (Metzinger-Le Meuth et al.,
2017). Recently, miR-223 has implied in the gene program of
osteoclastogenesis and macrophage differentiation during the
vascular calcification. This is a common complication in CKD
that affects the vascular system due to pathological deposition
of calcium and phosphate in the vessels (Metzinger-Le Meuth
et al., 2017). Also, Ulbing et al. (2017) have shown that
the expression of seric miR-223 is decreased in a murine
model of CKD; decreased levels of seric miR-223 are also
used to confirm CKD stage 4 and 5 diagnosis in patients
with CKD. In this context, the levels of miR-155, miR-125b,
and miR-145 are also decreased in stage 3-5D CKD patients
(Chen et al., 2013).
Microvesicles (Hunter et al., 2008) and exosomes (Valadi et al.,
2007) may actively play pathological roles in the development
and progression of CVDs because they act as carriers of various
miRNAs. miRNAs can be carried by RNA-binding proteins such
as Argonaute 2 (Arroyo et al., 2011), or lipoprotein complexes
such as HDL (Vickers et al., 2011). MiR-223 could be delivery, in
part linked to HDL, toward to intima and media wall and could
be transferred to ECs suppressing the expression of intercellular
adhesion molecule 1 (ICAM-1) (Metzinger-Le Meuth et al.,
2017). Accordingly, the results of our previous study show that
both strands of miR-126 are encapsulated in endothelial MVs,
and that vascular endothelial repair is mediated by miR-126 and
HIF-1α (Alique et al., 2019). Results reported that miRNAs are
involved in the senescence phenotype acquisition (Alique et al.,
2017, 2019; Carracedo et al., 2018b). Several miRNAs–mediated
pathological effects are described in Table 3.
MiR-145 is upregulated in the plasma of patients with
stable coronary artery disease, stable or unstable angina,
and acute myocardial infarction (Vacante et al., 2019).
Nonetheless, EVs contain-associated miR-143 acts as a
mediator of communication between ECs and VSMCs in
CVDs. miR-143 in particular is associated with vascular
remodeling in pulmonary arterial hypertension (Vacante
et al., 2019), while the miR-143/145 cluster, released from
VSMCs, modulates angiogenesis and EC proliferation (Climent
et al., 2015; Vacante et al., 2019). These findings indicate
that miR-143 and miR-145 regulate VSMCs phenotype and
mediate the development of vascular diseases. Therefore,
miRNA expression may be used as a biomarker of CKD-
associated CVDs, while modulation of this expression
can be used to develop novel therapeutic approaches
against these diseases.
MiR-21 is linked with VSMCs physiological proliferation
(Ballantyne et al., 2019) and kidney fibrosis because the
abrogation of miR-21 has been described as a protector against
the development of fibrosis (Metzinger-Le Meuth et al., 2017).
Furthermore, miR-21 is upregulated in ECs collected from
atheroma plaques and in progenitor cells obtained from patients
with coronary artery disease (Pfeifer et al., 2015). Hence, the
elimination of miR-21 could be a useful therapy to avoid the
development of kidney fibrosis, whereas this effect could be
hazardous for the normal VSMCs proliferation in the vessels.
In this regard, the developing localized therapies in the kidney
may reduce the risk of adverse events in this treatment approach
(Barwari et al., 2018).
CONCLUSION AND FUTURE
PERSPECTIVES
In this review, we discussed the cellular and molecular factors
involved in accelerated senescence that is observed in patients
with CKD. The aging process that occurs due to uremia
is associated with numerous changes at the cellular and
molecular level, which coincide with changes observed during
the physiological aging process. These changes may explain some
of the complications that typically occur in patients with CKD
and CKD-associated CVDs. Expanding our understanding of
the factors and molecules involved in accelerated senescence
will serve to identify possible targets associated with this
process. This will lead to improved methods of diagnosis and
monitoring of these patients. Understanding the similarities
between accelerated senescence and normal physiological aging
will help establish new treatments. Further studies are needed to
assess whether treatments aimed at delaying physiological aging
can be applied in CKD.
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